Sunshine Biopharma, Inc. (SBFMW)
| Market Cap | 2.48M -51.5% |
| Revenue (ttm) | 35.49M +4.1% |
| Net Income | -6.04M |
| EPS | -12.83 |
| Shares Out | 500.60K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173 |
| Open | 0.0310 |
| Previous Close | 0.0430 |
| Day's Range | 0.0310 - 0.0310 |
| 52-Week Range | 0.0160 - 0.6498 |
| Beta | 1.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About SBFMW
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurin... [Read more]
News
Sunshine Biopharma announces approval of generic Ondansetron tablets
Sunshine Biopharma (SBFM) announces the approval of its generic Ondansetron tablets of 4mg and 8mg for the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran. Sunshine…
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
FORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...
Sunshine Biopharma announces publication of new results on MR1-114
Sunshine Biopharma (SBFM) announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor, MR1-114, with nanomolar poten...
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
FORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...
Sunshine Biopharma receives Canadian approval for generic Arimidex
Sunshine Biopharma (SBFM) announced the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex...
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medic...
Sunshine Biopharma announces Canadian approval for Rivaroxaban
Sunshine Biopharma (SBFM) announces the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name…
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica...
Sunshine Biopharma Inc trading halted, news pending
19:50 EDT Sunshine Biopharma (SBFM) Inc trading halted, news pending
Sunshine Biopharma issued U.S. patent for coronavirus treatment tech
Sunshine Biopharma (SBFM) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled “Compounds and Methods for Treatment of Coronavirus Infection.” ...
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
FORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica...
Sunshine Biopharma announces 1-for-10 reverse split of its common stock
Sunshine Biopharma (SBFM) announced a one for ten reverse split of its common stock, effective at market open on June 1, 2026. The reverse stock split was undertaken to regain…
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
FORT LAUDERDALE, FL / ACCESS Newswire / May 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica...
Sunshine announces approval of generic amoxicillin formulation for Canada
Sunshine Biopharma (SBFM) announces the approval of its generic Amoxicillin formulation for the Canadian market. “This strategic expansion reinforces Sunshine Biopharma’s commitment to providing affor...
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
FORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica...
3 Penny Stocks to Watch Now, 5/19/26
GeoVax Labs ($GOVX), Roboai ($AIIO), and Sunshine Biopharma ($SBFM) are the three penny stocks to watch on May 19, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to…
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
$6.0 million upfront with up to an additional approximately $12.0 million of potential aggregate gross proceeds upon the exercise in full of warrants. FORT LAUDERDALE, FL / ACCESS Newswire / May 19, 2...
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
FORT LAUDERDALE, FL / ACCESS Newswire / May 18, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, an...
Why Is Penny Stock Sunshine Biopharma (SBFM) Up Today?
Sunshine Biopharma stock was up on Monday alongside heavy trading of SBFM shares.
Sunshine Biopharma files to sell 5.825M common units
Sunshine Biopharma (SBFM) is offering, on a best efforts basis, up to 5.825M common units, each common unit consisting of one share of common stock, and two Series C warrants,…
Sunshine Biopharma reports FY25 EPS ($1.44) vs. ($7.32) last year
Reports revenue $36.3M vs. $34.9M last year. “We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future,” said Dr. Steve Slilaty,…
Sunshine Biopharma expects to reduce expenses by $2M-$3M in 2026
The company said, “In January 2026, Sunshine Biopharma (SBFM) implemented cost-reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company’s focus on achievi...
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medi...
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ: SBFM) is quickly establishing which side of that...
Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidone
Sunshine Biopharma’s (SBFM) Nora Pharma has received approval from Health Canada for the commercialization of Domperidone, a prescription medication used to relieve nausea and vomiting and to enhance ...